Skip to Main Content

Author Details

Vladimir Makarov
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
2001
82
43
PMIDPaper TitleJournal TitlePublished Year
36927002Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.J Clin Oncol2023
37620627Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.Nat Med2023
37252795The MIF promoter SNP rs755622 is associated with immune activation in glioblastoma.JCI Insight2023
37066116Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.Oncoimmunology2023
36927002Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.J Clin Oncol2023
37529400Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic Vulnerabilities.Cancer Res Commun2023
37529400Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic Vulnerabilities.Cancer Res Commun2023
37620627Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.Nat Med2023
37252795The MIF promoter SNP rs755622 is associated with immune activation in glioblastoma.JCI Insight2023
37066116Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.Oncoimmunology2023
34725502Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Nat Biotechnol2022
36362093Comparison of EMT-Related and Multi-Drug Resistant Gene Expression, Extracellular Matrix Production, and Drug Sensitivity in NSCLC Spheroids Generated by Scaffold-Free and Scaffold-Based Methods.Int J Mol Sci2022
35584120H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.Proc Natl Acad Sci U S A2022
35758895A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.Cancer Discov2022
35817971Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Nat Genet2022
35731870Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma.Sci Adv2022
35472075Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids.Cancer Res2022
36252564Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.J Immunother Cancer2022
35398668Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.Neoplasia2022
36536472Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.Genome Med2022
34789562Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity.Mol Cancer Ther2022
34725502Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Nat Biotechnol2022
34635506Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy.Mol Cancer Res2022
35584120H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.Proc Natl Acad Sci U S A2022
35472075Colorectal Cancer Develops Inherent Radiosensitivity That Can Be Predicted Using Patient-Derived Organoids.Cancer Res2022
35731870Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma.Sci Adv2022
35398668Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells.Neoplasia2022
35758895A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.Cancer Discov2022
35817971Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.Nat Genet2022
36536472Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.Genome Med2022
36362093Comparison of EMT-Related and Multi-Drug Resistant Gene Expression, Extracellular Matrix Production, and Drug Sensitivity in NSCLC Spheroids Generated by Scaffold-Free and Scaffold-Based Methods.Int J Mol Sci2022
36252564Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.J Immunother Cancer2022
34789562Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity.Mol Cancer Ther2022
34635506Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy.Mol Cancer Res2022
33323400The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.Clin Cancer Res2021
31813809Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.Eur Urol Focus2021
33861994Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.Cancer Cell2021
33834176Mutations in <i>BRCA1</i> and <i>BRCA2</i> differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.Nat Cancer2021
34039647High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Mol Cancer Res2021
34316321Resource-efficient pooled sequencing expands translational impact in solid tumors.Kidney Cancer J2021
33323400The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.Clin Cancer Res2021
33861994Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.Cancer Cell2021
33834176Mutations in <i>BRCA1</i> and <i>BRCA2</i> differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.Nat Cancer2021
34039647High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.Mol Cancer Res2021
34316321Resource-efficient pooled sequencing expands translational impact in solid tumors.Kidney Cancer J2021
31813809Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.Eur Urol Focus2021
32220885Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.Clin Cancer Res2020
32220885Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression.Clin Cancer Res2020
32455715Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype.Cancers (Basel)2020
32444418Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.Clin Cancer Res2020
  • 1 - 50 of 164

Recommended Authors

Kuan-Lin Huang
Icahn School of Medicine at Mount Sinai
Career Start Year 2013
Number of shared co-authors 1
Ignaty Leshchiner
Broad Institute of Massachusetts Institute of Technology and Harvard
Career Start Year 2008
Number of shared co-authors 8
Hannah Carter
University of California San Diego
Career Start Year 2008
Number of shared co-authors 6
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 14
Mark J Cowley
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2006
Number of shared co-authors 6
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Career Start Year 2006
Number of shared co-authors 7
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 14
Robert C Onofrio
The Broad Institute of Harvard and MIT
Career Start Year 2005
Number of shared co-authors 24
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 7
Ann-Marie Patch
QIMR Berghofer Medical Research Institute
Career Start Year 2005
Number of shared co-authors 8
Matthias Schlesner
University of Augsburg
Career Start Year 2004
Number of shared co-authors 1
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 3
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 6
Malachi Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 7
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 12
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Peter Van Loo
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 8
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 9
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 28
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Career Start Year 2000
Number of shared co-authors 33
Yan W Asmann
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 4
Celine Lefebvre
The Scripps Research Institute
Career Start Year 1999
Number of shared co-authors 5
Carrie Sougnez
The Broad Institute of Harvard and MIT
Career Start Year 1998
Number of shared co-authors 32
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 9
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 24
John V Pearson
QIMR Berghofer Medical Research Institute
Career Start Year 1996
Number of shared co-authors 14
Curtis Gumbs
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 3
Marco A Marra
University of British Columbia
Career Start Year 1993
Number of shared co-authors 24
Elaine R Mardis
The Ohio State University
Career Start Year 1988
Number of shared co-authors 26
David A Wheeler
Baylor College of Medicine
Career Start Year 1984
Number of shared co-authors 48

Collaborators

Timothy A Chan
Cleveland Clinic.
Co-authored papers 42
Nadeem Riaz
Memorial Sloan Kettering Cancer Center
Co-authored papers 23
Luc G T Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 20
Fengshen Kuo
Memorial Sloan Kettering Cancer Center
Co-authored papers 20
Joseph D Buxbaum
Icahn School of Medicine at Mount Sinai
Co-authored papers 14
Seungtai Yoon
Co-authored papers 10
Abraham Ari Hakimi
Co-authored papers 8
Alan L Ho
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 5
Nora Katabi
Memorial Sloan Kettering Cancer Center
Co-authored papers 5
Jonathan Sebat
University of California San Diego
Co-authored papers 5
Michael F Berger
Co-authored papers 5
Benjamin D Greenbaum
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Guiqing Cai
Co-authored papers 4
James S Sutcliffe
Vanderbilt Genetics Institute, Vanderbilt University
Co-authored papers 4
Eric J Sherman
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Abhishek Bhandari
B.P. Koirala Institute of Health Sciences
Co-authored papers 4
Victor E Reuter
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Niels Weinhold
Co-authored papers 4
Shane McCarthy
Wellcome Sanger Institute
Co-authored papers 4
Dheeraj Malhotra
MS Research Unit
Co-authored papers 4
Xihong Lin
Harvard T.H. Chan School of Public Health
Co-authored papers 3
Leslie Cope
Johns Hopkins University School of Medicine
Co-authored papers 3
Mark J Daly
Massachusetts General Hospital
Co-authored papers 3
Kathryn Roeder
Co-authored papers 3
Mary-Claire King
University of Washington
Co-authored papers 3
Michael Gill
Co-authored papers 3
Gerard D Schellenberg
Co-authored papers 3
Bernie Devlin
Co-authored papers 3
Mark Lee
Memorial Sloan Kettering Cancer Center (MSKCC)
Co-authored papers 3
Release 1.2